HIV Infections
Conditions
Keywords
HIV-infection, AIDS, antiretroviral treatment, CD4 cell count, plasma HIV, RNA, SARS-CoV-2, antibodies
Brief summary
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.
Interventions
OTHERBlood Sample
Blood Sample
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* adults (\> 18 years) * HIV-infected patients * subjects with social insurance * subjects able to understand study purposes, and to give a written and informed consent
Exclusion criteria
: * subjects unable to understand informations on the study, and to provide informed consent * subjects under guardianship or curatorship * subjects under judicial protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroprevalence of SARS-CoV-2 | From baseline to 12 months | SARS-CoV-2 antibodies will be detected with a rapid test detecting IgG and IgM, at inclusion, and during a 6-month and a 12-month visit, in order to assess the prevalence of the virus in this population. |
Countries
France
Outcome results
None listed